We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inovio (INO) Reports Wider Loss in Q3, Revenues Beat
Read MoreHide Full Article
Plymouth Meeting, PA-based Inovio Pharmaceuticals, Inc. (INO - Free Report) is a development-stage biopharmaceutical company focused on the development of active DNA immunotherapies and vaccines targeting various cancer forms and infectious diseases. Inovio has several early- and mid-stage candidates in its pipeline.
VGX-3100 is the most advanced candidate in the company’s pipeline. It has completed a phase II study on VGX-3100 for the treatment of cervical dysplasia. Apart from VGX-3100, the company has several other candidates in its pipeline. Interesting candidates include INO-5150 (phase I – prostate cancer), INO-1400 (phase I – breast, lung and pancreatic cancers) and INO-3112 (phase I/II – head/neck cancer and cervical cancers) among others.
With Inovio not having any approved product in its portfolio, Inovio depends entirely on collaborations, grants and government contracts for revenues. In this scenario, investor focus will remain on pipeline and regulatory updates.
In the trailing four quarters, Inovio’s performance has been mixed with the company recording an average positive surprise of 205.15%. While the company surpassed estimates on three occasions, it missed expectations in the remaining one.
Currently, Inovio has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Inovio reported a loss of 28 cents in the third quarter of 2016, marginally wider than the Zacks Consensus Estimates of a loss of 26 cents.
Revenues: Revenues in the reported quarter came in above expectations. Inovio posted revenues of $12.5 million, compared to our consensus estimate of $4 million.
Key Stats: VGX-3100 is the most advanced candidate in the company’s pipeline. Last month, Inovio suffered a setback with the FDA placing a clinical hold on its late-stage program for VGX-3100. The company was looking to move VGX-3100 into phase III development in the fourth quarter but with the clinical hold in place, it now expects the program to be delayed until the first half of 2017 pending resolution of the FDA’s requests.
Stock Price: Inactive in pre-market trading.
Check back later for our full write up on earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Inovio (INO) Reports Wider Loss in Q3, Revenues Beat
Plymouth Meeting, PA-based Inovio Pharmaceuticals, Inc. (INO - Free Report) is a development-stage biopharmaceutical company focused on the development of active DNA immunotherapies and vaccines targeting various cancer forms and infectious diseases. Inovio has several early- and mid-stage candidates in its pipeline.
VGX-3100 is the most advanced candidate in the company’s pipeline. It has completed a phase II study on VGX-3100 for the treatment of cervical dysplasia. Apart from VGX-3100, the company has several other candidates in its pipeline. Interesting candidates include INO-5150 (phase I – prostate cancer), INO-1400 (phase I – breast, lung and pancreatic cancers) and INO-3112 (phase I/II – head/neck cancer and cervical cancers) among others.
With Inovio not having any approved product in its portfolio, Inovio depends entirely on collaborations, grants and government contracts for revenues. In this scenario, investor focus will remain on pipeline and regulatory updates.
In the trailing four quarters, Inovio’s performance has been mixed with the company recording an average positive surprise of 205.15%. While the company surpassed estimates on three occasions, it missed expectations in the remaining one.
INOVIO PHARMAC Price and EPS Surprise
INOVIO PHARMAC Price and EPS Surprise | INOVIO PHARMAC Quote
Currently, Inovio has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Inovio reported a loss of 28 cents in the third quarter of 2016, marginally wider than the Zacks Consensus Estimates of a loss of 26 cents.
Revenues: Revenues in the reported quarter came in above expectations. Inovio posted revenues of $12.5 million, compared to our consensus estimate of $4 million.
Key Stats: VGX-3100 is the most advanced candidate in the company’s pipeline. Last month, Inovio suffered a setback with the FDA placing a clinical hold on its late-stage program for VGX-3100. The company was looking to move VGX-3100 into phase III development in the fourth quarter but with the clinical hold in place, it now expects the program to be delayed until the first half of 2017 pending resolution of the FDA’s requests.
Stock Price: Inactive in pre-market trading.
Check back later for our full write up on earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>